Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 1
2001 1
2002 1
2003 2
2004 2
2005 1
2006 3
2007 1
2008 3
2009 6
2010 2
2011 5
2012 9
2013 6
2014 4
2015 9
2016 3
2017 2
2019 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Results by year
Filters applied: . Clear all
Page 1
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: hoeflich kp. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP. Hatlen MA, et al. Among authors: hoeflich kp. Cancer Discov. 2019 Dec;9(12):1686-1695. doi: 10.1158/2159-8290.CD-19-0367. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575540 Free article.
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. Hatzivassiliou G, et al. Among authors: hoeflich kp. Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3. Nature. 2010. PMID: 20130576
p21-activated kinase inhibitors.
Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J. Rudolph J, et al. Among authors: hoeflich kp. Enzymes. 2013;34 Pt. B:157-80. doi: 10.1016/B978-0-12-420146-0.00007-X. Epub 2013 Nov 7. Enzymes. 2013. PMID: 25034104 Review.
Targeting cancer with kinase inhibitors.
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Gross S, et al. Among authors: hoeflich kp. J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1. J Clin Invest. 2015. PMID: 25932675 Free PMC article. Review.
p21-activated kinase 1: PAK'ed with potential.
Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H, Hoeflich KP. Ong CC, et al. Among authors: hoeflich kp. Oncotarget. 2011 Jun;2(6):491-6. doi: 10.18632/oncotarget.271. Oncotarget. 2011. PMID: 21653999 Free PMC article. Review.
p21-Activated kinase inhibitors: a patent review.
Crawford JJ, Hoeflich KP, Rudolph J. Crawford JJ, et al. Among authors: hoeflich kp. Expert Opin Ther Pat. 2012 Mar;22(3):293-310. doi: 10.1517/13543776.2012.668758. Epub 2012 Mar 11. Expert Opin Ther Pat. 2012. PMID: 22404134 Review.
Radixin: cytoskeletal adopter and signaling protein.
Hoeflich KP, Ikura M. Hoeflich KP, et al. Int J Biochem Cell Biol. 2004 Nov;36(11):2131-6. doi: 10.1016/j.biocel.2003.11.018. Int J Biochem Cell Biol. 2004. PMID: 15313460 Review.
61 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page